The world’s first digital therapeutic for temporomandibular joint (TMJ) disorder.
A 6-week prescription program combining jaw exercises, behavioral therapy, and pain tracking—all connected through a clinician monitoring system.
6
Week program
10
Minutes daily
1
Clinician dashboard
Trusted by clinical and regulatory partners
The Problem
TMD is common, and current care is hard to sustain.
Temporomandibular disorder affects millions of patients worldwide. Conventional treatment often requires repeated in-person visits, and long-term adherence to home exercises is difficult to maintain without support.
1 in 10
Adults affected
TMD is one of the most common chronic orofacial pain conditions.
Repeated
In-person visits
Standard care relies on recurring chairside follow-up.
Low
Home adherence
Unsupervised exercise programs see steep drop-off over time.
Our Solution
Clickless: the world's first prescribed, monitored digital therapy for TMD
Patients use the Clickless app for 10 minutes a day for 6 weeks. The program combines jaw exercise, behavioral therapy, pain tracking, and patient education, while clinicians monitor progress through a dedicated dashboard.
Diagnosis
01
Prescription
02
Patient App
03
Daily Therapy
04
Clinician Dashboard
05
Follow-up
06
Diagnosis
Prescription
Patient App
Daily Therapy
Clinician Dashboard
Follow-up
How Care Is Delivered
Clinical expertise, extended by software
Clickless pairs a licensed clinician's diagnosis and oversight with AI-driven feedback the patient carries home. Neither replaces the other.
Clinician-Led Care
A licensed clinician diagnoses TMD, prescribes Clickless, and reviews adherence and outcomes through a dedicated dashboard throughout the 6-week program.
AI-Powered Software
Smartphone motion sensing gives patients real-time exercise feedback at home, while daily pain and adherence data flow back to the care team automatically.
Clinical Evidence
Built on clinical trial data, not assumptions
Clickless is being evaluated through structured clinical research, from randomized trials to real-world adherence tracking.
Randomized Controlled Trial
A multicenter, double-blind, sham-controlled RCT evaluated Clickless against a matched sham app in patients with confirmed TMD, with both arms receiving conventional care.
Peer-Reviewed Publications
Findings are published in the Journal of Medical Internet Research, Journal of Dentistry, and Archives of Clinical and Medical Case Reports.
Patient Adherence
Daily engagement was tracked across the full 6-week program to measure real-world program completion.
Pain Reduction
Patient-reported pain scores were measured at baseline and at program completion using validated instruments.
Regulatory Progress
A deliberate path to global clearance
Beyondmedicine is pursuing regulatory approval market by market, building a foundation for long-term global availability.
Korea Approval
Korea ApprovalClickless is the world's first digital therapeutic authorized for TMD, cleared through Korea's regulatory process for digital therapeutic medical devices.
FDA De Novo Pathway
FDA De Novo PathwayBeyondmedicine is preparing a submission through the FDA De Novo classification pathway for the US market.
Global Expansion
Future plans include CE marking in Europe and PMDA review in Japan.
Why Beyondmedicine
A digital therapeutics company built for the long term
Evidence-Based
Every claim is grounded in clinical study data, not marketing language.
Clinician-Centered
Built with dentists and OMFS surgeons, for the way clinics actually work.
Digital Therapeutics
The world's first regulated digital therapeutic for TMD, prescribed and monitored like any therapy.
AI-Enabled Future
A data platform built to support predictive, personalized care as it scales globally.